NLRP3 and mesothelioma: Similarly, it has been shown that in mesothelioma tumors that exhibit attenuated NLRP3 inflammasome activation, doxorubicin and cisplatin activate the NLRP3/caspase-1 signaling pathway to activate pyroptosis and suppress tumor proliferation [70].